Literature references that cite this PDB file's
key reference
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
X.Sun,
E.A.Barlow,
S.Ma,
S.R.Hagemeier,
S.J.Duellman,
R.R.Burgess,
J.Tellam,
R.Khanna,
and
S.C.Kenney
(2010).
Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism.
|
| |
Proc Natl Acad Sci U S A, 107,
3146-3151.
|
 |
|
|
|
|
 |
A.Ito,
H.Saito,
K.Mitobe,
Y.Minamiya,
N.Takahashi,
K.Maruyama,
S.Motoyama,
Y.Katayose,
and
J.Ogawa
(2009).
Inhibition of heat shock protein 90 sensitizes melanoma cells to thermosensitive ferromagnetic particle-mediated hyperthermia with low Curie temperature.
|
| |
Cancer Sci, 100,
558-564.
|
 |
|
|
|
|
 |
B.H.Kang,
and
D.C.Altieri
(2009).
Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones.
|
| |
Oncogene, 28,
3681-3688.
|
 |
|
|
|
|
 |
B.T.Scroggins,
and
L.Neckers
(2009).
Just say NO: nitric oxide regulation of Hsp90.
|
| |
EMBO Rep, 10,
1093-1094.
|
 |
|
|
|
|
 |
C.Graf,
M.Stankiewicz,
G.Kramer,
and
M.P.Mayer
(2009).
Spatially and kinetically resolved changes in the conformational dynamics of the Hsp90 chaperone machine.
|
| |
EMBO J, 28,
602-613.
|
 |
|
|
|
|
 |
C.K.Vaughan,
P.W.Piper,
L.H.Pearl,
and
C.Prodromou
(2009).
A common conformationally coupled ATPase mechanism for yeast and human cytoplasmic HSP90s.
|
| |
FEBS J, 276,
199-209.
|
 |
|
|
|
|
 |
D.A.Hubert,
Y.He,
B.C.McNulty,
P.Tornero,
and
J.L.Dangl
(2009).
Specific Arabidopsis HSP90.2 alleles recapitulate RAR1 cochaperone function in plant NB-LRR disease resistance protein regulation.
|
| |
Proc Natl Acad Sci U S A, 106,
9556-9563.
|
 |
|
|
|
|
 |
E.S.Ehrlich,
T.Wang,
K.Luo,
Z.Xiao,
A.M.Niewiadomska,
T.Martinez,
W.Xu,
L.Neckers,
and
X.F.Yu
(2009).
Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase.
|
| |
Proc Natl Acad Sci U S A, 106,
20330-20335.
|
 |
|
|
|
|
 |
S.Eichner,
H.G.Floss,
F.Sasse,
and
A.Kirschning
(2009).
New, highly active nonbenzoquinone geldanamycin derivatives by using mutasynthesis.
|
| |
Chembiochem, 10,
1801-1805.
|
 |
|
|
|
|
 |
S.Jiang,
L.Qiu,
F.Zhou,
J.Huang,
Y.Guo,
and
K.Yang
(2009).
Molecular cloning and expression analysis of a heat shock protein (Hsp90) gene from black tiger shrimp (Penaeus monodon).
|
| |
Mol Biol Rep, 36,
127-134.
|
 |
|
|
|
|
 |
T.Wenyong,
L.Lu,
C.Daozhen,
Y.Weidong,
and
H.Ying
(2009).
An experimental study on the antitumor effect of (131)I-17-AAG in vitro and in vivo.
|
| |
Ann Nucl Med, 23,
113-122.
|
 |
|
|
|
|
 |
X.Chen,
H.Kang,
and
F.Zou
(2009).
Low concentration of GA activates a preconditioning response in HepG2 cells during oxidative stress-roles of Hsp90 and vimentin.
|
| |
Cell Stress Chaperones, 14,
381-389.
|
 |
|
|
|
|
 |
Z.Chang
(2009).
Posttranslational modulation on the biological activities of molecular chaperones.
|
| |
Sci China C Life Sci, 52,
515-520.
|
 |
|
|
|
|
 |
A.Leskovar,
H.Wegele,
N.D.Werbeck,
J.Buchner,
and
J.Reinstein
(2008).
The ATPase cycle of the mitochondrial Hsp90 analog Trap1.
|
| |
J Biol Chem, 283,
11677-11688.
|
 |
|
|
|
|
 |
A.M.Nicola,
R.V.Andrade,
A.S.Dantas,
P.A.Andrade,
F.B.Arraes,
L.Fernandes,
I.Silva-Pereira,
and
M.S.Felipe
(2008).
The stress responsive and morphologically regulated hsp90 gene from Paracoccidioides brasiliensis is essential to cell viability.
|
| |
BMC Microbiol, 8,
158.
|
 |
|
|
|
|
 |
A.Yan,
G.H.Grant,
and
W.G.Richards
(2008).
Dynamics of conserved waters in human Hsp90: implications for drug design.
|
| |
J R Soc Interface, 5,
S199-S205.
|
 |
|
|
|
|
 |
C.Liu,
C.Erlichman,
C.J.McDonald,
J.N.Ingle,
P.Zollman,
I.Iankov,
S.J.Russell,
and
E.Galanis
(2008).
Heat shock protein inhibitors increase the efficacy of measles virotherapy.
|
| |
Gene Ther, 15,
1024-1034.
|
 |
|
|
|
|
 |
D.Y.He,
and
D.Ron
(2008).
Glial cell line-derived neurotrophic factor reverses ethanol-mediated increases in tyrosine hydroxylase immunoreactivity via altering the activity of heat shock protein 90.
|
| |
J Biol Chem, 283,
12811-12818.
|
 |
|
|
|
|
 |
K.Lee,
J.S.Ryu,
Y.Jin,
W.Kim,
N.Kaur,
S.J.Chung,
Y.J.Jeon,
J.T.Park,
J.S.Bang,
H.S.Lee,
T.Y.Kim,
J.J.Lee,
and
Y.S.Hong
(2008).
Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
|
| |
Org Biomol Chem, 6,
340-348.
|
 |
|
|
|
|
 |
K.Sugimoto,
M.Sasaki,
Y.Isobe,
M.Tsutsui,
H.Suto,
J.Ando,
K.Tamayose,
M.Ando,
and
K.Oshimi
(2008).
Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.
|
| |
Oncogene, 27,
3091-3101.
|
 |
|
|
|
|
 |
L.Liu,
R.Srikakulam,
and
D.A.Winkelmann
(2008).
Unc45 activates Hsp90-dependent folding of the myosin motor domain.
|
| |
J Biol Chem, 283,
13185-13193.
|
 |
|
|
|
|
 |
M.Futami,
T.Hatano,
Y.Soda,
S.Kobayashi,
M.Miyagishi,
and
A.Tojo
(2008).
RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
|
| |
Leukemia, 22,
1131-1138.
|
 |
|
|
|
|
 |
M.Imoto
(2008).
[Bioprobe generation from microbial origin for chemical biology study]
|
| |
Nippon Yakurigaku Zasshi, 132,
26-30.
|
 |
|
|
|
|
 |
M.Kosmaoglou,
N.Schwarz,
J.S.Bett,
and
M.E.Cheetham
(2008).
Molecular chaperones and photoreceptor function.
|
| |
Prog Retin Eye Res, 27,
434-449.
|
 |
|
|
|
|
 |
M.Sgobba,
G.Degliesposti,
A.M.Ferrari,
and
G.Rastelli
(2008).
Structural models and binding site prediction of the C-terminal domain of human Hsp90: a new target for anticancer drugs.
|
| |
Chem Biol Drug Des, 71,
420-433.
|
 |
|
|
|
|
 |
M.Zhang,
M.Botër,
K.Li,
Y.Kadota,
B.Panaretou,
C.Prodromou,
K.Shirasu,
and
L.H.Pearl
(2008).
Structural and functional coupling of Hsp90- and Sgt1-centred multi-protein complexes.
|
| |
EMBO J, 27,
2789-2798.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.K.Wandinger,
K.Richter,
and
J.Buchner
(2008).
The Hsp90 chaperone machinery.
|
| |
J Biol Chem, 283,
18473-18477.
|
 |
|
|
|
|
 |
T.Kobayakawa,
S.Yamada,
A.Mizuno,
and
T.K.Nemoto
(2008).
Substitution of only two residues of human Hsp90alpha causes impeded dimerization of Hsp90beta.
|
| |
Cell Stress Chaperones, 13,
97.
|
 |
|
|
|
|
 |
U.Banerji,
N.Sain,
S.Y.Sharp,
M.Valenti,
Y.Asad,
R.Ruddle,
F.Raynaud,
M.Walton,
S.A.Eccles,
I.Judson,
A.L.Jackman,
and
P.Workman
(2008).
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
|
| |
Cancer Chemother Pharmacol, 62,
769-778.
|
 |
|
|
|
|
 |
W.He,
J.Lei,
Y.Liu,
and
Y.Wang
(2008).
The LuxR family members GdmRI and GdmRII are positive regulators of geldanamycin biosynthesis in Streptomyces hygroscopicus 17997.
|
| |
Arch Microbiol, 189,
501-510.
|
 |
|
|
|
|
 |
Y.Peng,
X.Liu,
and
D.R.Schoenberg
(2008).
The 90-kDa Heat Shock Protein Stabilizes the Polysomal Ribonuclease 1 mRNA Endonuclease to Degradation by the 26S Proteasome.
|
| |
Mol Biol Cell, 19,
546-552.
|
 |
|
|
|
|
 |
A.Dey,
and
A.I.Cederbaum
(2007).
Geldanamycin, an inhibitor of Hsp90 increases cytochrome P450 2E1 mediated toxicity in HepG2 cells through sustained activation of the p38MAPK pathway.
|
| |
Arch Biochem Biophys, 461,
275-286.
|
 |
|
|
|
|
 |
C.A.Kyratsous,
and
S.J.Silverstein
(2007).
BAG3, a host cochaperone, facilitates varicella-zoster virus replication.
|
| |
J Virol, 81,
7491-7503.
|
 |
|
|
|
|
 |
C.S.McErlean,
N.Proisy,
C.J.Davis,
N.A.Boland,
S.Y.Sharp,
K.Boxall,
A.M.Slawin,
P.Workman,
and
C.J.Moody
(2007).
Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
|
| |
Org Biomol Chem, 5,
531-546.
|
 |
|
|
|
|
 |
D.Matei,
M.Satpathy,
L.Cao,
Y.C.Lai,
H.Nakshatri,
and
D.B.Donner
(2007).
The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.
|
| |
J Biol Chem, 282,
445-453.
|
 |
|
|
|
|
 |
H.Zhang,
Y.C.Yang,
L.Zhang,
J.Fan,
D.Chung,
D.Choi,
R.Grecko,
G.Timony,
P.Karjian,
M.Boehm,
and
F.Burrows
(2007).
Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
|
| |
Int J Cancer, 120,
918-926.
|
 |
|
|
|
|
 |
J.R.Huth,
C.Park,
A.M.Petros,
A.R.Kunzer,
M.D.Wendt,
X.Wang,
C.L.Lynch,
J.C.Mack,
K.M.Swift,
R.A.Judge,
J.Chen,
P.L.Richardson,
S.Jin,
S.K.Tahir,
E.D.Matayoshi,
S.A.Dorwin,
U.S.Ladror,
J.M.Severin,
K.A.Walter,
D.M.Bartley,
S.W.Fesik,
S.W.Elmore,
and
P.J.Hajduk
(2007).
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
|
| |
Chem Biol Drug Des, 70,
1.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Galam,
M.K.Hadden,
Z.Ma,
Q.Z.Ye,
B.G.Yun,
B.S.Blagg,
and
R.L.Matts
(2007).
High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.
|
| |
Bioorg Med Chem, 15,
1939-1946.
|
 |
|
|
|
|
 |
N.Wayne,
and
D.N.Bolon
(2007).
Dimerization of Hsp90 is required for in vivo function. Design and analysis of monomers and dimers.
|
| |
J Biol Chem, 282,
35386-35395.
|
 |
|
|
|
|
 |
P.L.Yeyati,
R.M.Bancewicz,
J.Maule,
and
V.van Heyningen
(2007).
Hsp90 selectively modulates phenotype in vertebrate development.
|
| |
PLoS Genet, 3,
e43.
|
 |
|
|
|
|
 |
S.Frey,
A.Leskovar,
J.Reinstein,
and
J.Buchner
(2007).
The ATPase cycle of the endoplasmic chaperone Grp94.
|
| |
J Biol Chem, 282,
35612-35620.
|
 |
|
|
|
|
 |
T.A.Sangster,
A.Bahrami,
A.Wilczek,
E.Watanabe,
K.Schellenberg,
C.McLellan,
A.Kelley,
S.W.Kong,
C.Queitsch,
and
S.Lindquist
(2007).
Phenotypic diversity and altered environmental plasticity in Arabidopsis thaliana with reduced Hsp90 levels.
|
| |
PLoS ONE, 2,
e648.
|
 |
|
|
|
|
 |
W.Kim,
J.S.Lee,
D.Lee,
X.F.Cai,
J.C.Shin,
K.Lee,
C.H.Lee,
S.Ryu,
S.G.Paik,
J.J.Lee,
and
Y.S.Hong
(2007).
Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring.
|
| |
Chembiochem, 8,
1491-1494.
|
 |
|
|
|
|
 |
A.C.Fan,
M.K.Bhangoo,
and
J.C.Young
(2006).
Hsp90 functions in the targeting and outer membrane translocation steps of Tom70-mediated mitochondrial import.
|
| |
J Biol Chem, 281,
33313-33324.
|
 |
|
|
|
|
 |
B.R.Keppler,
A.T.Grady,
and
M.B.Jarstfer
(2006).
The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity.
|
| |
J Biol Chem, 281,
19840-19848.
|
 |
|
|
|
|
 |
B.S.Blagg,
and
T.D.Kerr
(2006).
Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
|
| |
Med Res Rev, 26,
310-338.
|
 |
|
|
|
|
 |
C.W.Olanow,
and
K.S.McNaught
(2006).
Ubiquitin-proteasome system and Parkinson's disease.
|
| |
Mov Disord, 21,
1806-1823.
|
 |
|
|
|
|
 |
C.Y.Chen,
and
W.E.Balch
(2006).
The Hsp90 chaperone complex regulates GDI-dependent Rab recycling.
|
| |
Mol Biol Cell, 17,
3494-3507.
|
 |
|
|
|
|
 |
D.Fedunová,
and
M.Antalík
(2006).
Prevention of thermal induced aggregation of cytochrome c at isoelectric pH values by polyanions.
|
| |
Biotechnol Bioeng, 93,
485-493.
|
 |
|
|
|
|
 |
D.Rajagopal,
V.Bal,
S.Mayor,
A.George,
and
S.Rath
(2006).
A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules.
|
| |
Eur J Immunol, 36,
828-841.
|
 |
|
|
|
|
 |
F.Chu,
J.C.Maynard,
G.Chiosis,
C.V.Nicchitta,
and
A.L.Burlingame
(2006).
Identification of novel quaternary domain interactions in the Hsp90 chaperone, GRP94.
|
| |
Protein Sci, 15,
1260-1269.
|
 |
|
|
|
|
 |
F.Shinozaki,
M.Minami,
T.Chiba,
M.Suzuki,
K.Yoshimatsu,
Y.Ichikawa,
K.Terasawa,
Y.Emori,
K.Matsumoto,
T.Kurosaki,
A.Nakai,
K.Tanaka,
and
Y.Minami
(2006).
Depletion of hsp90beta induces multiple defects in B cell receptor signaling.
|
| |
J Biol Chem, 281,
16361-16369.
|
 |
|
|
|
|
 |
J.Moreno-Farre,
Y.Asad,
S.Pacey,
P.Workman,
and
F.I.Raynaud
(2006).
Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma.
|
| |
Rapid Commun Mass Spectrom, 20,
2845-2850.
|
 |
|
|
|
|
 |
K.Richter,
S.Moser,
F.Hagn,
R.Friedrich,
O.Hainzl,
M.Heller,
S.Schlee,
H.Kessler,
J.Reinstein,
and
J.Buchner
(2006).
Intrinsic inhibition of the Hsp90 ATPase activity.
|
| |
J Biol Chem, 281,
11301-11311.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Terasawa,
K.Yoshimatsu,
S.Iemura,
T.Natsume,
K.Tanaka,
and
Y.Minami
(2006).
Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases.
|
| |
Mol Cell Biol, 26,
3378-3389.
|
 |
|
|
|
|
 |
K.Yang,
H.Shi,
R.Qi,
S.Sun,
Y.Tang,
B.Zhang,
and
C.Wang
(2006).
Hsp90 regulates activation of interferon regulatory factor 3 and TBK-1 stabilization in Sendai virus-infected cells.
|
| |
Mol Biol Cell, 17,
1461-1471.
|
 |
|
|
|
|
 |
L.H.Pearl,
and
C.Prodromou
(2006).
Structure and mechanism of the Hsp90 molecular chaperone machinery.
|
| |
Annu Rev Biochem, 75,
271-294.
|
 |
|
|
|
|
 |
L.T.Gooljarsingh,
C.Fernandes,
K.Yan,
H.Zhang,
M.Grooms,
K.Johanson,
R.H.Sinnamon,
R.B.Kirkpatrick,
J.Kerrigan,
T.Lewis,
M.Arnone,
A.J.King,
Z.Lai,
R.A.Copeland,
and
P.J.Tummino
(2006).
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues.
|
| |
Proc Natl Acad Sci U S A, 103,
7625-7630.
|
 |
|
|
|
|
 |
M.A.Fares,
and
S.A.Travers
(2006).
A novel method for detecting intramolecular coevolution: adding a further dimension to selective constraints analyses.
|
| |
Genetics, 173,
9.
|
 |
|
|
|
|
 |
M.A.Martinez-Yamout,
R.P.Venkitakrishnan,
N.E.Preece,
G.Kroon,
P.E.Wright,
and
H.J.Dyson
(2006).
Localization of sites of interaction between p23 and Hsp90 in solution.
|
| |
J Biol Chem, 281,
14457-14464.
|
 |
|
|
|
|
 |
M.A.Theodoraki,
and
A.C.Mintzas
(2006).
cDNA cloning, heat shock regulation and developmental expression of the hsp83 gene in the Mediterranean fruit fly Ceratitis capitata.
|
| |
Insect Mol Biol, 15,
839-852.
|
 |
|
|
|
|
 |
M.D.Amaral
(2006).
Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease.
|
| |
J Inherit Metab Dis, 29,
477-487.
|
 |
|
|
|
|
 |
M.G.Catlett,
and
K.B.Kaplan
(2006).
Sgt1p is a unique co-chaperone that acts as a client adaptor to link Hsp90 to Skp1p.
|
| |
J Biol Chem, 281,
33739-33748.
|
 |
|
|
|
|
 |
M.M.Ali,
S.M.Roe,
C.K.Vaughan,
P.Meyer,
B.Panaretou,
P.W.Piper,
C.Prodromou,
and
L.H.Pearl
(2006).
Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex.
|
| |
Nature, 440,
1013-1017.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.W.Graner,
and
D.D.Bigner
(2006).
Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.
|
| |
Expert Rev Anticancer Ther, 6,
679-695.
|
 |
|
|
|
|
 |
M.Waza,
H.Adachi,
M.Katsuno,
M.Minamiyama,
F.Tanaka,
M.Doyu,
and
G.Sobue
(2006).
Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.
|
| |
J Mol Med, 84,
635-646.
|
 |
|
|
|
|
 |
P.Hawle,
M.Siepmann,
A.Harst,
M.Siderius,
H.P.Reusch,
and
W.M.Obermann
(2006).
The middle domain of Hsp90 acts as a discriminator between different types of client proteins.
|
| |
Mol Cell Biol, 26,
8385-8395.
|
 |
|
|
|
|
 |
R.K.Allan,
D.Mok,
B.K.Ward,
and
T.Ratajczak
(2006).
Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization.
|
| |
J Biol Chem, 281,
7161-7171.
|
 |
|
|
|
|
 |
S.Chaudhury,
T.R.Welch,
and
B.S.Blagg
(2006).
Hsp90 as a target for drug development.
|
| |
ChemMedChem, 1,
1331-1340.
|
 |
|
|
|
|
 |
S.Cotesta,
and
M.Stahl
(2006).
The environment of amide groups in protein-ligand complexes: H-bonds and beyond.
|
| |
J Mol Model, 12,
436-444.
|
 |
|
|
|
|
 |
T.S.Kim,
C.Y.Jang,
H.D.Kim,
J.Y.Lee,
B.Y.Ahn,
and
J.Kim
(2006).
Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation.
|
| |
Mol Biol Cell, 17,
824-833.
|
 |
|
|
|
|
 |
V.Barresi,
C.G.Fortuna,
R.Garozzo,
G.Musumarra,
S.Scirè,
and
D.F.Condorelli
(2006).
Identification of genes involved in the sensitivity to antitumour drug 17-allylamino,17-demethoxygeldanamycin (17AAG).
|
| |
Mol Biosyst, 2,
231-239.
|
 |
|
|
|
|
 |
V.Debat,
C.C.Milton,
S.Rutherford,
C.P.Klingenberg,
and
A.A.Hoffmann
(2006).
Hsp90 and the quantitative variation of wing shape in Drosophila melanogaster.
|
| |
Evolution Int J Org Evolution, 60,
2529-2538.
|
 |
|
|
|
|
 |
Y.Niikura,
S.Ohta,
K.J.Vandenbeldt,
R.Abdulle,
B.F.McEwen,
and
K.Kitagawa
(2006).
17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation.
|
| |
Oncogene, 25,
4133-4146.
|
 |
|
|
|
|
 |
A.Hardcastle,
K.Boxall,
J.Richards,
P.Tomlin,
S.Sharp,
P.Clarke,
P.Workman,
and
W.Aherne
(2005).
Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
|
| |
Assay Drug Dev Technol, 3,
273-285.
|
 |
|
|
|
|
 |
A.M.Skantar,
K.Agama,
S.L.Meyer,
L.K.Carta,
and
B.T.Vinyard
(2005).
Effects of geldanamycin on hatching and juvenile motility in Caenorhabditis elegans and Heterodera glycines.
|
| |
J Chem Ecol, 31,
2481-2491.
|
 |
|
|
|
|
 |
C.Sõti,
E.Nagy,
Z.Giricz,
L.Vígh,
P.Csermely,
and
P.Ferdinandy
(2005).
Heat shock proteins as emerging therapeutic targets.
|
| |
Br J Pharmacol, 146,
769-780.
|
 |
|
|
|
|
 |
D.Gadelle,
C.Bocs,
M.Graille,
and
P.Forterre
(2005).
Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol.
|
| |
Nucleic Acids Res, 33,
2310-2317.
|
 |
|
|
|
|
 |
H.Machida,
S.Nakajima,
N.Shikano,
J.Nishio,
S.Okada,
M.Asayama,
M.Shirai,
and
N.Kubota
(2005).
Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis.
|
| |
Cancer Sci, 96,
911-917.
|
 |
|
|
|
|
 |
J.Kishimoto,
Y.Fukuma,
A.Mizuno,
and
T.K.Nemoto
(2005).
Identification of the pentapeptide constituting a dominant epitope common to all eukaryotic heat shock protein 90 molecular chaperones.
|
| |
Cell Stress Chaperones, 10,
296-311.
|
 |
|
|
|
|
 |
J.L.Eiseman,
J.Lan,
T.F.Lagattuta,
D.R.Hamburger,
E.Joseph,
J.M.Covey,
and
M.J.Egorin
(2005).
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
|
| |
Cancer Chemother Pharmacol, 55,
21-32.
|
 |
|
|
|
|
 |
L.Whitesell,
and
S.L.Lindquist
(2005).
HSP90 and the chaperoning of cancer.
|
| |
Nat Rev Cancer, 5,
761-772.
|
 |
|
|
|
|
 |
M.Kato,
J.L.Chuang,
S.C.Tso,
R.M.Wynn,
and
D.T.Chuang
(2005).
Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl domain 2 of human pyruvate dehydrogenase complex.
|
| |
EMBO J, 24,
1763-1774.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.A.Konstantinopoulos,
and
A.G.Papavassiliou
(2005).
17-AAG: mechanisms of antitumour activity.
|
| |
Expert Opin Investig Drugs, 14,
1471-1474.
|
 |
|
|
|
|
 |
P.J.Muchowski,
and
J.L.Wacker
(2005).
Modulation of neurodegeneration by molecular chaperones.
|
| |
Nat Rev Neurosci, 6,
11-22.
|
 |
|
|
|
|
 |
P.J.Murphy,
Y.Morishima,
J.J.Kovacs,
T.P.Yao,
and
W.B.Pratt
(2005).
Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone.
|
| |
J Biol Chem, 280,
33792-33799.
|
 |
|
|
|
|
 |
P.Workman
(2005).
Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.
|
| |
Cold Spring Harb Symp Quant Biol, 70,
499-515.
|
 |
|
|
|
|
 |
R.F.Duncan
(2005).
Inhibition of Hsp90 function delays and impairs recovery from heat shock.
|
| |
FEBS J, 272,
5244-5256.
|
 |
|
|
|
|
 |
R.Zhang,
D.Luo,
R.Miao,
L.Bai,
Q.Ge,
W.C.Sessa,
and
W.Min
(2005).
Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis.
|
| |
Oncogene, 24,
3954-3963.
|
 |
|
|
|
|
 |
S.H.Millson,
A.W.Truman,
V.King,
C.Prodromou,
L.H.Pearl,
and
P.W.Piper
(2005).
A two-hybrid screen of the yeast proteome for Hsp90 interactors uncovers a novel Hsp90 chaperone requirement in the activity of a stress-activated mitogen-activated protein kinase, Slt2p (Mpk1p).
|
| |
Eukaryot Cell, 4,
849-860.
|
 |
|
|
|
|
 |
V.Smith,
E.A.Sausville,
R.F.Camalier,
H.H.Fiebig,
and
A.M.Burger
(2005).
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
|
| |
Cancer Chemother Pharmacol, 56,
126-137.
|
 |
|
|
|
|
 |
Y.Matsumoto,
H.Machida,
and
N.Kubota
(2005).
Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin.
|
| |
J Radiat Res (Tokyo), 46,
215-221.
|
 |
|
|
|
|
 |
A.R.Buskirk,
Y.C.Ong,
Z.J.Gartner,
and
D.R.Liu
(2004).
Directed evolution of ligand dependence: small-molecule-activated protein splicing.
|
| |
Proc Natl Acad Sci U S A, 101,
10505-10510.
|
 |
|
|
|
|
 |
C.Elbi,
D.A.Walker,
G.Romero,
W.P.Sullivan,
D.O.Toft,
G.L.Hager,
and
D.B.DeFranco
(2004).
Molecular chaperones function as steroid receptor nuclear mobility factors.
|
| |
Proc Natl Acad Sci U S A, 101,
2876-2881.
|
 |
|
|
|
|
 |
E.Pedone,
B.Ren,
R.Ladenstein,
M.Rossi,
and
S.Bartolucci
(2004).
Functional properties of the protein disulfide oxidoreductase from the archaeon Pyrococcus furiosus: a member of a novel protein family related to protein disulfide-isomerase.
|
| |
Eur J Biochem, 271,
3437-3448.
|
 |
|
|
|
|
 |
G.Siligardi,
B.Hu,
B.Panaretou,
P.W.Piper,
L.H.Pearl,
and
C.Prodromou
(2004).
Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle.
|
| |
J Biol Chem, 279,
51989-51998.
|
 |
|
|
|
|
 |
J.S.Bell,
T.I.Harvey,
A.M.Sims,
and
R.McCulloch
(2004).
Characterization of components of the mismatch repair machinery in Trypanosoma brucei.
|
| |
Mol Microbiol, 51,
159-173.
|
 |
|
|
|
|
 |
J.S.Isaacs,
Y.J.Jung,
and
L.Neckers
(2004).
Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1alpha by modulating an Hsp90-dependent regulatory pathway.
|
| |
J Biol Chem, 279,
16128-16135.
|
 |
|
|
|
|
 |
L.Müller,
A.Schaupp,
D.Walerych,
H.Wegele,
and
J.Buchner
(2004).
Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures.
|
| |
J Biol Chem, 279,
48846-48854.
|
 |
|
|
|
|
 |
L.Yan,
R.L.Cerny,
and
J.D.Cirillo
(2004).
Evidence that hsp90 is involved in the altered interactions of Acanthamoeba castellanii variants with bacteria.
|
| |
Eukaryot Cell, 3,
567-578.
|
 |
|
|
|
|
 |
L.Zhong,
K.Qing,
Y.Si,
L.Chen,
M.Tan,
and
A.Srivastava
(2004).
Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90.
|
| |
J Biol Chem, 279,
12714-12723.
|
 |
|
|
|
|
 |
M.Bedin,
A.M.Gaben,
C.Saucier,
and
J.Mester
(2004).
Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest.
|
| |
Int J Cancer, 109,
643-652.
|
 |
|
|
|
|
 |
M.Schroda
(2004).
The Chlamydomonas genome reveals its secrets: chaperone genes and the potential roles of their gene products in the chloroplast.
|
| |
Photosynth Res, 82,
221-240.
|
 |
|
|
|
|
 |
N.Tahbaz,
F.A.Kolb,
H.Zhang,
K.Jaronczyk,
W.Filipowicz,
and
T.C.Hobman
(2004).
Characterization of the interactions between mammalian PAZ PIWI domain proteins and Dicer.
|
| |
EMBO Rep, 5,
189-194.
|
 |
|
|
|
|
 |
P.E.Carrigan,
G.M.Nelson,
P.J.Roberts,
J.Stoffer,
D.L.Riggs,
and
D.F.Smith
(2004).
Multiple domains of the co-chaperone Hop are important for Hsp70 binding.
|
| |
J Biol Chem, 279,
16185-16193.
|
 |
|
|
|
|
 |
P.Meyer,
C.Prodromou,
C.Liao,
B.Hu,
S.Mark Roe,
C.K.Vaughan,
I.Vlasic,
B.Panaretou,
P.W.Piper,
and
L.H.Pearl
(2004).
Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery.
|
| |
EMBO J, 23,
511-519.
|
 |
|
|
|
|
 |
R.M.Immormino,
D.E.Dollins,
P.L.Shaffer,
K.L.Soldano,
M.A.Walker,
and
D.T.Gewirth
(2004).
Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 chaperone.
|
| |
J Biol Chem, 279,
46162-46171.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Bellon,
J.D.Parsons,
Y.Wei,
K.Hayakawa,
L.L.Swenson,
P.S.Charifson,
J.A.Lippke,
R.Aldape,
and
C.H.Gross
(2004).
Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.
|
| |
Antimicrob Agents Chemother, 48,
1856-1864.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.S.Billecke,
D.I.Draganov,
Y.Morishima,
P.J.Murphy,
A.Y.Dunbar,
W.B.Pratt,
and
Y.Osawa
(2004).
The role of hsp90 in heme-dependent activation of apo-neuronal nitric-oxide synthase.
|
| |
J Biol Chem, 279,
30252-30258.
|
 |
|
|
|
|
 |
T.Gidalevitz,
C.Biswas,
H.Ding,
D.Schneidman-Duhovny,
H.J.Wolfson,
F.Stevens,
S.Radford,
and
Y.Argon
(2004).
Identification of the N-terminal peptide binding site of glucose-regulated protein 94.
|
| |
J Biol Chem, 279,
16543-16552.
|
 |
|
|
|
|
 |
T.Prince,
and
R.L.Matts
(2004).
Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37.
|
| |
J Biol Chem, 279,
39975-39981.
|
 |
|
|
|
|
 |
Y.H.Li,
P.Z.Tao,
Y.Z.Liu,
and
J.D.Jiang
(2004).
Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro.
|
| |
Antimicrob Agents Chemother, 48,
867-872.
|
 |
|
|
|
|
 |
Y.Zhang,
J.S.Wang,
L.L.Chen,
Y.Zhang,
X.K.Cheng,
F.Y.Heng,
N.H.Wu,
and
Y.F.Shen
(2004).
Repression of hsp90beta gene by p53 in UV irradiation-induced apoptosis of Jurkat cells.
|
| |
J Biol Chem, 279,
42545-42551.
|
 |
|
|
|
|
 |
A.J.Caplan,
S.Jackson,
and
D.Smith
(2003).
Hsp90 reaches new heights. Conference on the Hsp90 chaperone machine.
|
| |
EMBO Rep, 4,
126-130.
|
 |
|
|
|
|
 |
A.Kamal,
L.Thao,
J.Sensintaffar,
L.Zhang,
M.F.Boehm,
L.C.Fritz,
and
F.J.Burrows
(2003).
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
|
| |
Nature, 425,
407-410.
|
 |
|
|
|
|
 |
B.T.Scroggins,
T.Prince,
J.Shao,
S.Uma,
W.Huang,
Y.Guo,
B.G.Yun,
K.Hedman,
R.L.Matts,
and
S.D.Hartson
(2003).
High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients.
|
| |
Biochemistry, 42,
12550-12561.
|
 |
|
|
|
|
 |
C.L.David,
H.E.Smith,
D.A.Raynes,
E.J.Pulcini,
and
L.Whitesell
(2003).
Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans.
|
| |
Cell Stress Chaperones, 8,
93.
|
 |
|
|
|
|
 |
C.Soti,
A.Vermes,
T.A.Haystead,
and
P.Csermely
(2003).
Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATP-binding site.
|
| |
Eur J Biochem, 270,
2421-2428.
|
 |
|
|
|
|
 |
D.A.Hubert,
P.Tornero,
Y.Belkhadir,
P.Krishna,
A.Takahashi,
K.Shirasu,
and
J.L.Dangl
(2003).
Cytosolic HSP90 associates with and modulates the Arabidopsis RPM1 disease resistance protein.
|
| |
EMBO J, 22,
5679-5689.
|
 |
|
|
|
|
 |
D.Gadelle,
J.Filée,
C.Buhler,
and
P.Forterre
(2003).
Phylogenomics of type II DNA topoisomerases.
|
| |
Bioessays, 25,
232-242.
|
 |
|
|
|
|
 |
G.P.Lotz,
H.Lin,
A.Harst,
and
W.M.Obermann
(2003).
Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone.
|
| |
J Biol Chem, 278,
17228-17235.
|
 |
|
|
|
|
 |
H.Ecroyd,
R.C.Jones,
and
R.J.Aitken
(2003).
Tyrosine phosphorylation of HSP-90 during mammalian sperm capacitation.
|
| |
Biol Reprod, 69,
1801-1807.
|
 |
|
|
|
|
 |
H.Ishiwatari-Hayasaka,
M.Maruya,
A.S.Sreedhar,
T.K.Nemoto,
P.Csermely,
and
I.Yahara
(2003).
Interaction of neuropeptide Y and Hsp90 through a novel peptide binding region.
|
| |
Biochemistry, 42,
12972-12980.
|
 |
|
|
|
|
 |
H.Wegele,
P.Muschler,
M.Bunck,
J.Reinstein,
and
J.Buchner
(2003).
Dissection of the contribution of individual domains to the ATPase mechanism of Hsp90.
|
| |
J Biol Chem, 278,
39303-39310.
|
 |
|
|
|
|
 |
K.F.Winklhofer,
U.Heller,
A.Reintjes,
and
J.Tatzelt
(2003).
Inhibition of complex glycosylation increases the formation of PrPsc.
|
| |
Traffic, 4,
313-322.
|
 |
|
|
|
|
 |
K.L.Soldano,
A.Jivan,
C.V.Nicchitta,
and
D.T.Gewirth
(2003).
Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation.
|
| |
J Biol Chem, 278,
48330-48338.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.N.Kinch,
Y.Qi,
T.J.Hubbard,
and
N.V.Grishin
(2003).
CASP5 target classification.
|
| |
Proteins, 53,
340-351.
|
 |
|
|
|
|
 |
L.Wang,
W.Sullivan,
D.Toft,
and
R.Weinshilboum
(2003).
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation.
|
| |
Pharmacogenetics, 13,
555-564.
|
 |
|
|
|
|
 |
P.Fortugno,
E.Beltrami,
J.Plescia,
J.Fontana,
D.Pradhan,
P.C.Marchisio,
W.C.Sessa,
and
D.C.Altieri
(2003).
Regulation of survivin function by Hsp90.
|
| |
Proc Natl Acad Sci U S A, 100,
13791-13796.
|
 |
|
|
|
|
 |
P.W.Piper,
S.H.Millson,
M.Mollapour,
B.Panaretou,
G.Siligardi,
L.H.Pearl,
and
C.Prodromou
(2003).
Sensitivity to Hsp90-targeting drugs can arise with mutation to the Hsp90 chaperone, cochaperones and plasma membrane ATP binding cassette transporters of yeast.
|
| |
Eur J Biochem, 270,
4689-4695.
|
 |
|
|
|
|
 |
P.de Candia,
D.B.Solit,
D.Giri,
E.Brogi,
P.M.Siegel,
A.B.Olshen,
W.J.Muller,
N.Rosen,
and
R.Benezra
(2003).
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors.
|
| |
Proc Natl Acad Sci U S A, 100,
12337-12342.
|
 |
|
|
|
|
 |
R.Kumar,
A.Musiyenko,
and
S.Barik
(2003).
The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin.
|
| |
Malar J, 2,
30.
|
 |
|
|
|
|
 |
S.Bandhakavi,
R.O.McCann,
D.E.Hanna,
and
C.V.Glover
(2003).
A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases.
|
| |
J Biol Chem, 278,
2829-2836.
|
 |
|
|
|
|
 |
S.J.Arlander,
A.K.Eapen,
B.T.Vroman,
R.J.McDonald,
D.O.Toft,
and
L.M.Karnitz
(2003).
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
|
| |
J Biol Chem, 278,
52572-52577.
|
 |
|
|
|
|
 |
S.Yamada,
T.Ono,
A.Mizuno,
and
T.K.Nemoto
(2003).
A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone.
|
| |
Eur J Biochem, 270,
146-154.
|
 |
|
|
|
|
 |
T.Vanden Berghe,
M.Kalai,
G.van Loo,
W.Declercq,
and
P.Vandenabeele
(2003).
Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis.
|
| |
J Biol Chem, 278,
5622-5629.
|
 |
|
|
|
|
 |
Y.Hiromasa,
and
T.E.Roche
(2003).
Facilitated interaction between the pyruvate dehydrogenase kinase isoform 2 and the dihydrolipoyl acetyltransferase.
|
| |
J Biol Chem, 278,
33681-33693.
|
 |
|
|
|
|
 |
Y.Miyata
(2003).
[Molecular chaperone HSP90 as a novel target for cancer chemotherapy]
|
| |
Nippon Yakurigaku Zasshi, 121,
33-42.
|
 |
|
|
|
|
 |
A.D.Basso,
D.B.Solit,
G.Chiosis,
B.Giri,
P.Tsichlis,
and
N.Rosen
(2002).
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.
|
| |
J Biol Chem, 277,
39858-39866.
|
 |
|
|
|
|
 |
A.Maloney,
and
P.Workman
(2002).
HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
|
| |
Expert Opin Biol Ther, 2,
3.
|
 |
|
|
|
|
 |
B.A.Owen,
W.P.Sullivan,
S.J.Felts,
and
D.O.Toft
(2002).
Regulation of heat shock protein 90 ATPase activity by sequences in the carboxyl terminus.
|
| |
J Biol Chem, 277,
7086-7091.
|
 |
|
|
|
|
 |
C.Garnier,
D.Lafitte,
P.O.Tsvetkov,
P.Barbier,
J.Leclerc-Devin,
J.M.Millot,
C.Briand,
A.A.Makarov,
M.G.Catelli,
and
V.Peyrot
(2002).
Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain.
|
| |
J Biol Chem, 277,
12208-12214.
|
 |
|
|
|
|
 |
C.Söti,
A.Rácz,
and
P.Csermely
(2002).
A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket.
|
| |
J Biol Chem, 277,
7066-7075.
|
 |
|
|
|
|
 |
C.Welz-Voegele,
J.E.Stone,
P.T.Tran,
H.M.Kearney,
R.M.Liskay,
T.D.Petes,
and
S.Jinks-Robertson
(2002).
Alleles of the yeast Pms1 mismatch-repair gene that differentially affect recombination- and replication-related processes.
|
| |
Genetics, 162,
1131-1145.
|
 |
|
|
|
|
 |
D.Liu,
O.C.Hutchinson,
S.Osman,
P.Price,
P.Workman,
and
E.O.Aboagye
(2002).
Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin.
|
| |
Br J Cancer, 87,
783-789.
|
 |
|
|
|
|
 |
J.C.Baker-LePain,
M.Sarzotti,
T.A.Fields,
C.Y.Li,
and
C.V.Nicchitta
(2002).
GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression.
|
| |
J Exp Med, 196,
1447-1459.
|
 |
|
|
|
|
 |
J.Hu,
D.Toft,
D.Anselmo,
and
X.Wang
(2002).
In vitro reconstitution of functional hepadnavirus reverse transcriptase with cellular chaperone proteins.
|
| |
J Virol, 76,
269-279.
|
 |
|
|
|
|
 |
J.J.Hung,
C.S.Chung,
and
W.Chang
(2002).
Molecular chaperone Hsp90 is important for vaccinia virus growth in cells.
|
| |
J Virol, 76,
1379-1390.
|
 |
|
|
|
|
 |
J.S.Isaacs,
Y.J.Jung,
E.G.Mimnaugh,
A.Martinez,
F.Cuttitta,
and
L.M.Neckers
(2002).
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway.
|
| |
J Biol Chem, 277,
29936-29944.
|
 |
|
|
|
|
 |
K.C.Kanelakis,
D.S.Shewach,
and
W.B.Pratt
(2002).
Nucleotide binding states of hsp70 and hsp90 during sequential steps in the process of glucocorticoid receptor.hsp90 heterocomplex assembly.
|
| |
J Biol Chem, 277,
33698-33703.
|
 |
|
|
|
|
 |
K.Richter,
J.Reinstein,
and
J.Buchner
(2002).
N-terminal residues regulate the catalytic efficiency of the Hsp90 ATPase cycle.
|
| |
J Biol Chem, 277,
44905-44910.
|
 |
|
|
|
|
 |
M.Räschle,
P.Dufner,
G.Marra,
and
J.Jiricny
(2002).
Mutations within the hMLH1 and hPMS2 subunits of the human MutLalpha mismatch repair factor affect its ATPase activity, but not its ability to interact with hMutSalpha.
|
| |
J Biol Chem, 277,
21810-21820.
|
 |
|
|
|
|
 |
P.Chène
(2002).
ATPases as drug targets: learning from their structure.
|
| |
Nat Rev Drug Discov, 1,
665-673.
|
 |
|
|
|
|
 |
P.Srivastava
(2002).
Roles of heat-shock proteins in innate and adaptive immunity.
|
| |
Nat Rev Immunol, 2,
185-194.
|
 |
|
|
|
|
 |
P.Srivastava
(2002).
Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses.
|
| |
Annu Rev Immunol, 20,
395-425.
|
 |
|
|
|
|
 |
S.Matsumoto,
E.Tanaka,
T.K.Nemoto,
T.Ono,
T.Takagi,
J.Imai,
Y.Kimura,
I.Yahara,
T.Kobayakawa,
T.Ayuse,
K.Oi,
and
A.Mizuno
(2002).
Interaction between the N-terminal and middle regions is essential for the in vivo function of HSP90 molecular chaperone.
|
| |
J Biol Chem, 277,
34959-34966.
|
 |
|
|
|
|
 |
S.Vogen,
T.Gidalevitz,
C.Biswas,
B.B.Simen,
E.Stein,
F.Gulmen,
and
Y.Argon
(2002).
Radicicol-sensitive peptide binding to the N-terminal portion of GRP94.
|
| |
J Biol Chem, 277,
40742-40750.
|
 |
|
|
|
|
 |
S.Walter,
and
J.Buchner
(2002).
Molecular chaperones--cellular machines for protein folding.
|
| |
Angew Chem Int Ed Engl, 41,
1098-1113.
|
 |
|
|
|
|
 |
T.Sakisaka,
T.Meerlo,
J.Matteson,
H.Plutner,
and
W.E.Balch
(2002).
Rab-alphaGDI activity is regulated by a Hsp90 chaperone complex.
|
| |
EMBO J, 21,
6125-6135.
|
 |
|
|
|
|
 |
T.Yamano,
S.Murata,
N.Shimbara,
N.Tanaka,
T.Chiba,
K.Tanaka,
K.Yui,
and
H.Udono
(2002).
Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing.
|
| |
J Exp Med, 196,
185-196.
|
 |
|
|
|
|
 |
A.Guarné,
M.S.Junop,
and
W.Yang
(2001).
Structure and function of the N-terminal 40 kDa fragment of human PMS2: a monomeric GHL ATPase.
|
| |
EMBO J, 20,
5521-5531.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.P.Demchenko
(2001).
Recognition between flexible protein molecules: induced and assisted folding.
|
| |
J Mol Recognit, 14,
42-61.
|
 |
|
|
|
|
 |
C.D.Bishop,
W.R.Bates,
and
B.P.Brandhorst
(2001).
Regulation of metamorphosis in ascidians involves NO/cGMP signaling and HSP90.
|
| |
J Exp Zool, 289,
374-384.
|
 |
|
|
|
|
 |
C.Garnier,
D.Lafitte,
T.J.Jorgensen,
O.N.Jensen,
C.Briand,
and
V.Peyrot
(2001).
Phosphorylation and oligomerization states of native pig brain HSP90 studied by mass spectrometry.
|
| |
Eur J Biochem, 268,
2402-2407.
|
 |
|
|
|
|
 |
E.Tanaka,
T.K.Nemoto,
and
T.Ono
(2001).
Liberation of the intramolecular interaction as the mechanism of heat-induced activation of HSP90 molecular chaperone.
|
| |
Eur J Biochem, 268,
5270-5277.
|
 |
|
|
|
|
 |
F.Randow,
and
B.Seed
(2001).
Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability.
|
| |
Nat Cell Biol, 3,
891-896.
|
 |
|
|
|
|
 |
F.S.Goes,
and
J.Martin
(2001).
Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1.
|
| |
Eur J Biochem, 268,
2281-2289.
|
 |
|
|
|
|
 |
G.de Cárcer,
M.do Carmo Avides,
M.J.Lallena,
D.M.Glover,
and
C.González
(2001).
Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability.
|
| |
EMBO J, 20,
2878-2884.
|
 |
|
|
|
|
 |
H.J.Ochel,
K.Eichhorn,
and
G.Gademann
(2001).
Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
|
| |
Cell Stress Chaperones, 6,
105-112.
|
 |
|
|
|
|
 |
H.Singh-Jasuja,
N.Hilf,
D.Arnold-Schild,
and
H.Schild
(2001).
The role of heat shock proteins and their receptors in the activation of the immune system.
|
| |
Biol Chem, 382,
629-636.
|
 |
|
|
|
|
 |
J.C.Young,
I.Moarefi,
and
F.U.Hartl
(2001).
Hsp90: a specialized but essential protein-folding tool.
|
| |
J Cell Biol, 154,
267-273.
|
 |
|
|
|
|
 |
J.Frankel,
N.E.Williams,
E.M.Nelsen,
and
P.J.Keeling
(2001).
An evaluation of Hsp90 as a mediator of cortical patterning in Tetrahymena.
|
| |
J Eukaryot Microbiol, 48,
147-160.
|
 |
|
|
|
|
 |
J.Frydman
(2001).
Folding of newly translated proteins in vivo: the role of molecular chaperones.
|
| |
Annu Rev Biochem, 70,
603-647.
|
 |
|
|
|
|
 |
K.Richter,
and
J.Buchner
(2001).
Hsp90: chaperoning signal transduction.
|
| |
J Cell Physiol, 188,
281-290.
|
 |
|
|
|
|
 |
L.Bouhouche-Chatelier,
A.Chadli,
and
M.G.Catelli
(2001).
The N-terminal adenosine triphosphate binding domain of Hsp90 is necessary and sufficient for interaction with estrogen receptor.
|
| |
Cell Stress Chaperones, 6,
297-305.
|
 |
|
|
|
|
 |
L.Waxman,
M.Whitney,
B.A.Pollok,
L.C.Kuo,
and
P.L.Darke
(2001).
Host cell factor requirement for hepatitis C virus enzyme maturation.
|
| |
Proc Natl Acad Sci U S A, 98,
13931-13935.
|
 |
|
|
|
|
 |
M.C.Rosenhagen,
J.C.Young,
G.M.Wochnik,
A.S.Herr,
U.Schmidt,
F.U.Hartl,
F.Holsboer,
and
T.Rein
(2001).
Synergistic inhibition of the glucocorticoid receptor by radicicol and benzoquinone ansamycins.
|
| |
Biol Chem, 382,
499-504.
|
 |
|
|
|
|
 |
M.Minami,
M.Nakamura,
Y.Emori,
and
Y.Minami
(2001).
Both the N- and C-terminal chaperone sites of Hsp90 participate in protein refolding.
|
| |
Eur J Biochem, 268,
2520-2524.
|
 |
|
|
|
|
 |
N.A.Linderoth,
M.N.Simon,
N.A.Rodionova,
M.Cadene,
W.R.Laws,
B.T.Chait,
and
S.Sastry
(2001).
Biophysical analysis of the endoplasmic reticulum-resident chaperone/heat shock protein gp96/GRP94 and its complex with peptide antigen.
|
| |
Biochemistry, 40,
1483-1495.
|
 |
|
|
|
|
 |
P.T.Tran,
J.A.Simon,
and
R.M.Liskay
(2001).
Interactions of Exo1p with components of MutLalpha in Saccharomyces cerevisiae.
|
| |
Proc Natl Acad Sci U S A, 98,
9760-9765.
|
 |
|
|
|
|
 |
R.Vaiskunaite,
T.Kozasa,
and
T.A.Voyno-Yasenetskaya
(2001).
Interaction between the G alpha subunit of heterotrimeric G(12) protein and Hsp90 is required for G alpha(12) signaling.
|
| |
J Biol Chem, 276,
46088-46093.
|
 |
|
|
|
|
 |
S.D.Catz,
J.L.Johnson,
and
B.M.Babior
(2001).
Characterization of the nucleotide-binding capacity and the ATPase activity of the PIP3-binding protein JFC1.
|
| |
Proc Natl Acad Sci U S A, 98,
11230-11235.
|
 |
|
|
|
|
 |
S.W.Fewell,
K.J.Travers,
J.S.Weissman,
and
J.L.Brodsky
(2001).
The action of molecular chaperones in the early secretory pathway.
|
| |
Annu Rev Genet, 35,
149-191.
|
 |
|
|
|
|
 |
T.Iwamura,
M.Yoneyama,
K.Yamaguchi,
W.Suhara,
W.Mori,
K.Shiota,
Y.Okabe,
H.Namiki,
and
T.Fujita
(2001).
Induction of IRF-3/-7 kinase and NF-kappaB in response to double-stranded RNA and virus infection: common and unique pathways.
|
| |
Genes Cells, 6,
375-388.
|
 |
|
|
|
|
 |
T.K.Nemoto,
T.Ono,
T.Kobayakawa,
E.Tanaka,
T.T.Baba,
K.Tanaka,
T.Takagi,
and
T.Gotoh
(2001).
Domain-domain interactions of HtpG, an Escherichia coli homologue of eukaryotic HSP90 molecular chaperone.
|
| |
Eur J Biochem, 268,
5258-5269.
|
 |
|
|
|
|
 |
A.Chadli,
I.Bouhouche,
W.Sullivan,
B.Stensgard,
N.McMahon,
M.G.Catelli,
and
D.O.Toft
(2000).
Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90.
|
| |
Proc Natl Acad Sci U S A, 97,
12524-12529.
|
 |
|
|
|
|
 |
B.M.Lange,
A.Bachi,
M.Wilm,
and
C.González
(2000).
Hsp90 is a core centrosomal component and is required at different stages of the centrosome cycle in Drosophila and vertebrates.
|
| |
EMBO J, 19,
1252-1262.
|
 |
|
|
|
|
 |
C.Prodromou,
B.Panaretou,
S.Chohan,
G.Siligardi,
R.O'Brien,
J.E.Ladbury,
S.M.Roe,
P.W.Piper,
and
L.H.Pearl
(2000).
The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains.
|
| |
EMBO J, 19,
4383-4392.
|
 |
|
|
|
|
 |
C.Sarto,
P.A.Binz,
and
P.Mocarelli
(2000).
Heat shock proteins in human cancer.
|
| |
Electrophoresis, 21,
1218-1226.
|
 |
|
|
|
|
 |
G.Scholz,
S.D.Hartson,
K.Cartledge,
N.Hall,
J.Shao,
A.R.Dunn,
and
R.L.Matts
(2000).
p50(Cdc37) can buffer the temperature-sensitive properties of a mutant of Hck.
|
| |
Mol Cell Biol, 20,
6984-6995.
|
 |
|
|
|
|
 |
J.C.Young,
and
F.U.Hartl
(2000).
Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23.
|
| |
EMBO J, 19,
5930-5940.
|
 |
|
|
|
|
 |
J.Lewis,
A.Devin,
A.Miller,
Y.Lin,
Y.Rodriguez,
L.Neckers,
and
Z.G.Liu
(2000).
Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation.
|
| |
J Biol Chem, 275,
10519-10526.
|
 |
|
|
|
|
 |
K.S.Russell,
M.P.Haynes,
T.Caulin-Glaser,
J.Rosneck,
W.C.Sessa,
and
J.R.Bender
(2000).
Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release.
|
| |
J Biol Chem, 275,
5026-5030.
|
 |
|
|
|
|
 |
M.J.Bijlmakers,
and
M.Marsh
(2000).
Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck).
|
| |
Mol Biol Cell, 11,
1585-1595.
|
 |
|
|
|
|
 |
P.T.Tran,
and
R.M.Liskay
(2000).
Functional studies on the candidate ATPase domains of Saccharomyces cerevisiae MutLalpha.
|
| |
Mol Cell Biol, 20,
6390-6398.
|
 |
|
|
|
|
 |
S.Basu,
and
P.K.Srivastava
(2000).
Heat shock proteins: the fountainhead of innate and adaptive immune responses.
|
| |
Cell Stress Chaperones, 5,
443-451.
|
 |
|
|
|
|
 |
S.D.Hartson,
A.D.Irwin,
J.Shao,
B.T.Scroggins,
L.Volk,
W.Huang,
and
R.L.Matts
(2000).
p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules.
|
| |
Biochemistry, 39,
7631-7644.
|
 |
|
|
|
|
 |
S.J.Felts,
B.A.Owen,
P.Nguyen,
J.Trepel,
D.B.Donner,
and
D.O.Toft
(2000).
The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties.
|
| |
J Biol Chem, 275,
3305-3312.
|
 |
|
|
|
|
 |
S.Kimmins,
and
T.H.MacRae
(2000).
Maturation of steroid receptors: an example of functional cooperation among molecular chaperones and their associated proteins.
|
| |
Cell Stress Chaperones, 5,
76-86.
|
 |
|
|
|
|
 |
S.Sato,
N.Fujita,
and
T.Tsuruo
(2000).
Modulation of Akt kinase activity by binding to Hsp90.
|
| |
Proc Natl Acad Sci U S A, 97,
10832-10837.
|
 |
|
|
|
|
 |
T.Schnaider,
J.Somogyi,
P.Csermely,
and
M.Szamel
(2000).
The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
|
| |
Cell Stress Chaperones, 5,
52-61.
|
 |
|
|
|
|
 |
A.Carrello,
E.Ingley,
R.F.Minchin,
S.Tsai,
and
T.Ratajczak
(1999).
The common tetratricopeptide repeat acceptor site for steroid receptor-associated immunophilins and hop is located in the dimerization domain of Hsp90.
|
| |
J Biol Chem, 274,
2682-2689.
|
 |
|
|
|
|
 |
A.Chadli,
M.M.Ladjimi,
E.E.Baulieu,
and
M.G.Catelli
(1999).
Heat-induced oligomerization of the molecular chaperone Hsp90. Inhibition by ATP and geldanamycin and activation by transition metal oxyanions.
|
| |
J Biol Chem, 274,
4133-4139.
|
 |
|
|
|
|
 |
C.Prodromou,
G.Siligardi,
R.O'Brien,
D.N.Woolfson,
L.Regan,
B.Panaretou,
J.E.Ladbury,
P.W.Piper,
and
L.H.Pearl
(1999).
Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones.
|
| |
EMBO J, 18,
754-762.
|
 |
|
|
|
|
 |
D.F.Nathan,
M.H.Vos,
and
S.Lindquist
(1999).
Identification of SSF1, CNS1, and HCH1 as multicopy suppressors of a Saccharomyces cerevisiae Hsp90 loss-of-function mutation.
|
| |
Proc Natl Acad Sci U S A, 96,
1409-1414.
|
 |
|
|
|
|
 |
J.P.Grenert,
B.D.Johnson,
and
D.O.Toft
(1999).
The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes.
|
| |
J Biol Chem, 274,
17525-17533.
|
 |
|
|
|
|
 |
K.A.Morano,
and
D.J.Thiele
(1999).
The Sch9 protein kinase regulates Hsp90 chaperone complex signal transduction activity in vivo.
|
| |
EMBO J, 18,
5953-5962.
|
 |
|
|
|
|
 |
K.A.Morano,
N.Santoro,
K.A.Koch,
and
D.J.Thiele
(1999).
A trans-activation domain in yeast heat shock transcription factor is essential for cell cycle progression during stress.
|
| |
Mol Cell Biol, 19,
402-411.
|
 |
|
|
|
|
 |
K.I.Kang,
X.Meng,
J.Devin-Leclerc,
I.Bouhouche,
A.Chadli,
F.Cadepond,
E.E.Baulieu,
and
M.G.Catelli
(1999).
The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter.
|
| |
Proc Natl Acad Sci U S A, 96,
1439-1444.
|
 |
|
|
|
|
 |
L.Yue,
T.L.Karr,
D.F.Nathan,
H.Swift,
S.Srinivasan,
and
S.Lindquist
(1999).
Genetic analysis of viable Hsp90 alleles reveals a critical role in Drosophila spermatogenesis.
|
| |
Genetics, 151,
1065-1079.
|
 |
|
|
|
|
 |
M.D.Galigniana,
P.R.Housley,
D.B.DeFranco,
and
W.B.Pratt
(1999).
Inhibition of glucocorticoid receptor nucleocytoplasmic shuttling by okadaic acid requires intact cytoskeleton.
|
| |
J Biol Chem, 274,
16222-16227.
|
 |
|
|
|
|
 |
M.E.Cardenas,
M.C.Cruz,
M.Del Poeta,
N.Chung,
J.R.Perfect,
and
J.Heitman
(1999).
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.
|
| |
Clin Microbiol Rev, 12,
583-611.
|
 |
|
|
|
|
 |
M.J.Lees,
and
M.L.Whitelaw
(1999).
Multiple roles of ligand in transforming the dioxin receptor to an active basic helix-loop-helix/PAS transcription factor complex with the nuclear protein Arnt.
|
| |
Mol Cell Biol, 19,
5811-5822.
|
 |
|
|
|
|
 |
N.Grammatikakis,
J.H.Lin,
A.Grammatikakis,
P.N.Tsichlis,
and
B.H.Cochran
(1999).
p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function.
|
| |
Mol Cell Biol, 19,
1661-1672.
|
 |
|
|
|
|
 |
P.V.Shcherbakova,
and
T.A.Kunkel
(1999).
Mutator phenotypes conferred by MLH1 overexpression and by heterozygosity for mlh1 mutations.
|
| |
Mol Cell Biol, 19,
3177-3183.
|
 |
|
|
|
|
 |
R.Dutta,
L.Qin,
and
M.Inouye
(1999).
Histidine kinases: diversity of domain organization.
|
| |
Mol Microbiol, 34,
633-640.
|
 |
|
|
|
|
 |
S.D.Hartson,
V.Thulasiraman,
W.Huang,
L.Whitesell,
and
R.L.Matts
(1999).
Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates.
|
| |
Biochemistry, 38,
3837-3849.
|
 |
|
|
|
|
 |
S.E.Holt,
D.L.Aisner,
J.Baur,
V.M.Tesmer,
M.Dy,
M.Ouellette,
J.B.Trager,
G.B.Morin,
D.O.Toft,
J.W.Shay,
W.E.Wright,
and
M.A.White
(1999).
Functional requirement of p23 and Hsp90 in telomerase complexes.
|
| |
Genes Dev, 13,
817-826.
|
 |
|
|
|
|
 |
T.Scheibel,
H.I.Siegmund,
R.Jaenicke,
P.Ganz,
H.Lilie,
and
J.Buchner
(1999).
The charged region of Hsp90 modulates the function of the N-terminal domain.
|
| |
Proc Natl Acad Sci U S A, 96,
1297-1302.
|
 |
|
|
|
|
 |
T.Scheibel,
T.Weikl,
R.Rimerman,
D.Smith,
S.Lindquist,
and
J.Buchner
(1999).
Contribution of N- and C-terminal domains to the function of Hsp90 in Saccharomyces cerevisiae.
|
| |
Mol Microbiol, 34,
701-713.
|
 |
|
|
|
|
 |
A.Ali,
S.Bharadwaj,
R.O'Carroll,
and
N.Ovsenek
(1998).
HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes.
|
| |
Mol Cell Biol, 18,
4949-4960.
|
 |
|
|
|
|
 |
A.M.Silverstein,
N.Grammatikakis,
B.H.Cochran,
M.Chinkers,
and
W.B.Pratt
(1998).
p50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site.
|
| |
J Biol Chem, 273,
20090-20095.
|
 |
|
|
|
|
 |
B.D.Johnson,
R.J.Schumacher,
E.D.Ross,
and
D.O.Toft
(1998).
Hop modulates Hsp70/Hsp90 interactions in protein folding.
|
| |
J Biol Chem, 273,
3679-3686.
|
 |
|
|
|
|
 |
B.Gerhardt,
T.J.Kordas,
C.M.Thompson,
P.Patel,
and
T.Vida
(1998).
The vesicle transport protein Vps33p is an ATP-binding protein that localizes to the cytosol in an energy-dependent manner.
|
| |
J Biol Chem, 273,
15818-15829.
|
 |
|
|
|
|
 |
B.Panaretou,
C.Prodromou,
S.M.Roe,
R.O'Brien,
J.E.Ladbury,
P.W.Piper,
and
L.H.Pearl
(1998).
ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo.
|
| |
EMBO J, 17,
4829-4836.
|
 |
|
|
|
|
 |
H.Kosano,
B.Stensgard,
M.C.Charlesworth,
N.McMahon,
and
D.Toft
(1998).
The assembly of progesterone receptor-hsp90 complexes using purified proteins.
|
| |
J Biol Chem, 273,
32973-32979.
|
 |
|
|
|
|
 |
J.C.Milne,
A.C.Eliot,
N.L.Kelleher,
and
C.T.Walsh
(1998).
ATP/GTP hydrolysis is required for oxazole and thiazole biosynthesis in the peptide antibiotic microcin B17.
|
| |
Biochemistry, 37,
13250-13261.
|
 |
|
|
|
|
 |
J.C.Young,
W.M.Obermann,
and
F.U.Hartl
(1998).
Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90.
|
| |
J Biol Chem, 273,
18007-18010.
|
 |
|
|
|
|
 |
K.D.Dittmar,
M.Banach,
M.D.Galigniana,
and
W.B.Pratt
(1998).
The role of DnaJ-like proteins in glucocorticoid receptor.hsp90 heterocomplex assembly by the reconstituted hsp90.p60.hsp70 foldosome complex.
|
| |
J Biol Chem, 273,
7358-7366. |